EW
Edwards Lifesciences Corp
Latest Form 4:Sale$50KbyDahl Andrew M. (SVP, Corporate Controller) · filed Aug 31, 2026
Edwards Lifesciences Corp (EW) has 73 SEC Form 4 filings (153 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 31, 2026.
The most active filer is CVP, TAVR Lippis Daniel J. with 11 filings. Insiders have net sold $15.5M over the trailing 6 months.
- Industry:Medical - Devices
- CEO:Bernard J. Zovighian
- Employees:15,800
- HQ:Irvine, CA, US
- IPO:2000-03-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$27.6M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$52.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Dahl Andrew M.First in 3 months | SVP, Corporate Controller | Sale | 544 | $50K | Aug 31 | SEC ↗ |
Bruls AnnetteFirst filing | CVP, EMEACLA | Sale | 2,644 | $238K | Aug 28 | SEC ↗ |
| CVP, JAPAC | Sale | 1,240 | $113K | Aug 26 | SEC ↗ | |
Chopra DaveenFirst in 3 months | CVP, TMTT, Surgical & IHFM | Sale | 31,800 | $2.9M | Aug 26 | SEC ↗ |
| CVP, TAVR | Sale | 619 | $57K | Aug 11 | SEC ↗ | |
| CVP, JAPAC | Sale | 146.313 | $13K | Jul 30 | SEC ↗ | |
| CVP, JAPAC | Sale | 9,628 | $819K | Jul 28 | SEC ↗ | |
| CEO | Sale | 2,920.551 | $245K | Jul 27 | SEC ↗ | |
| CVP, TAVR | Sale | 619 | $57K | Jul 10 | SEC ↗ | |
| CVP, TAVR | Sale | 619 | $57K | Jul 1 | SEC ↗ | |
| CEO | Sale | 523 | $46K | Jun 17 | SEC ↗ | |
Dahl Andrew M.First filing | SVP, Corporate Controller | Sale | 567.527 | $49K | May 29 | SEC ↗ |
| CVP,Strategy/Corp Development | Sale | 23,145 | $2.0M | May 27 | SEC ↗ | |
Chopra DaveenFirst in 5 months | CVP, TMTT & Surgical | Sale | 1,500 | $127K | May 22 | SEC ↗ |
| CVP, TAVR | Sale | 620 | $50K | May 18 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 17,968 | $1.5M | May 18 | SEC ↗ | |
| CEO | Sale | 36,351 | $2.8M | May 12 | SEC ↗ | |
Markowitz WayneFirst in 5 months | CVP, JAPAC | Sale | 593 | $47K | May 12 | SEC ↗ |
| CVP, TAVR | Sale | 1,019 | $85K | May 4 | SEC ↗ | |
| CVP, TAVR | Sale | 1,019 | $86K | May 4 | SEC ↗ | |
| CVP, Chief Financial Officer | Sale | 13,000 | $1.0M | Apr 9 | SEC ↗ | |
| CVP, TAVR | Sale | 1,019 | $83K | Apr 6 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 22,680 | $1.8M | Apr 2 | SEC ↗ | |
Ullem Scott B.First in 3 months | CVP, Chief Financial Officer | Sale | 13,000 | $1.1M | Mar 11 | SEC ↗ |
| CVP, TAVR | Sale | 1,019 | $87K | Mar 11 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 11,340 | $974K | Mar 2 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 24,000 | $2.0M | Feb 26 | SEC ↗ | |
| CEO | Sale | 22,430 | $1.7M | Feb 13 | SEC ↗ | |
| CVP, TAVR | Sale | 1,019 | $87K | Jan 9 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 11,340 | $971K | Jan 6 | SEC ↗ | |
| CVP, JAPAC | Sale | 1,019 | $86K | Dec 12 | SEC ↗ | |
| CVP,Strategy/Corp Development | Sale | 11,386.118 | $954K | Dec 12 | SEC ↗ | |
STONE HEISZ LESLIEFirst filing | Director | Sale | 2,615 | $218K | Dec 12 | SEC ↗ |
Chopra DaveenFirst filing | CVP, TMTT & Surgical | Sale | 2,000 | $169K | Dec 11 | SEC ↗ |
Zovighian Bernard JFirst filing | CEO | Sale | 21,487 | $1.8M | Dec 10 | SEC ↗ |
Zovighian Bernard JFirst filing | CEO | Sale | 3,863 | $322K | Dec 10 | SEC ↗ |
BOBO DONALD E JRFirst filing | CVP,Strategy/Corp Development | Sale | 11,340 | $951K | Dec 10 | SEC ↗ |
| CVP, Chief Financial Officer | Sale | 7,700 | $650K | Dec 9 | SEC ↗ | |
Markowitz WayneFirst filing | CVP, JAPAC | Sale | 583 | $50K | Dec 8 | SEC ↗ |
Ullem Scott B.First filing | CVP, Chief Financial Officer | Sale | 13,000 | $1.1M | Nov 10 | SEC ↗ |
Lippis Daniel J.First filing | CVP, JAPAC | Sale | 1,020 | $84K | Nov 10 | SEC ↗ |
Congress trading EW
See timeline →- DRep. Ro KhannaPurchase$1,001 - $15,0002026-05-01
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
Edwards Lifesciences Corp is in the Manufacturing sector.